Genetic approach could help identify side-effects at early stages of drug development

An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated. The technique involves identifying genetic variants that mimic the action of a drug on its intended target and then checking in large patient cohorts whether these variants are associated with risk of other conditions, such as cardiovascular disease.